Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Spring Bank Pharmaceuticals at the Piper Jaffray 31st Annual Healthcare Conference  (Replay)
    Wednesday, December 04, 2019 9:00 am EST
Toggle Summary Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019
HOPKINTON, Mass. , Dec. 09, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced two hepatitis B virus
Toggle Summary Spring Bank Announces Dosing of Patients in Phase 1 Clinical Trial of IV-Administered STING Agonist, SB 11285
HOPKINTON, Mass. , Nov. 20, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has initiated
Toggle Summary Spring Bank Announces Investor Conference Presentations for the Remainder of 2019
HOPKINTON, Mass. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscoll ,
Toggle Summary Spring Bank Pharmaceuticals Reports Third Quarter 2019 Financial and Operational Results and Provides Corporate Update
Company to host conference call on Monday, November 11, 2019 at 4:30pm EST to discuss current HBV landscape and update on the company’s development programs HOPKINTON, Mass. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical
Toggle Summary Spring Bank Announces Interim Top-Line Results from the First Cohort of the Phase 2 Trial Evaluating Low-Dose Inarigivir Plus Vemlidy® in Chronic Hepatitis B Patients
7 of 30 patients were HBsAg responders with ≥ 0.5log₁₀ reduction Inarigivir 50mg plus Vemlidy® 25mg was generally safe and well tolerated at 12 weeks Evaluation of inarigivir 200mg and 400mg co-administered with Vemlidy is ongoing HOPKINTON, Mass. , Oct.
Toggle Summary Spring Bank to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York, NY
HOPKINTON, Mass. , Sept. 23, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscoll ,
Toggle Summary Yale Cancer Center to Present on the Synergistic Relationship Between Intravenously-Administered SB 11285, Spring Bank’s STING Agonist Development Compound, and Radiation Therapy in Cancer at the 2019 ASTRO Annual Meeting
HOPKINTON, Mass. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Dr.
Toggle Summary Spring Bank Announces $20 Million Strategic Debt Financing Agreement with Pontifax Medison Finance
Significant investment demonstrates confidence in Spring Bank’s novel development programs Extends Spring Bank’s cash runway beyond the end of 2021 Accelerates HBV antisense and STING antagonist development programs HOPKINTON, Mass. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals,
Toggle Summary Spring Bank Announces Collaborative Research Agreement with University of Texas Southwestern Medical School for Evaluation of STING Antagonist Compounds
HOPKINTON, Mass. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has entered into
Toggle Summary Spring Bank Pharmaceuticals Reports Second Quarter 2019 Financial and Operational Results and Provides Business Development Update
HOPKINTON, Mass. , July 31, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced its financial results for